Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.

Content Provider	Europe PMC
Author	Du, Yuxuan Chen, Long Shi, Yuan
Copyright Year	2022
Abstract	There is a wealth of data suggesting that the effectiveness of existing vaccines against the Omicron variant, the most mutated SARS-CoV-2 variant to date, has been substantially reduced if only primary vaccination is administered. Therefore, the effectiveness of booster vaccination against the Omicron variant has become a topic of current interest. We conducted a comprehensive search in PubMed, Embase, and the Cochrane Library to collect various pseudovirus neutralization tests or live virus neutralization tests for the Omicron variant, with serum specimens from booster vaccinees. We extracted neutralization titers for the Omicron variant, the original strain, and the other variants before and after booster vaccination, and then manually calculated the fold increase or decrease in neutralization titers for the Omicron variant relative to the other variants, and the fold increase in neutralization titers for the Omicron variant after booster vaccination compared with that before booster vaccination. In the two-dose vaccination regimen, the neutralization titers against the Omicron variant decreased substantially compared to the original strain and other variants. However, after booster vaccination, both homologous and heterologous booster vaccination, the neutralization of serum antibodies against the Omicron variant was significantly improved, although still lower than that of the original strain and other variants. The booster vaccination program based on existing vaccines can produce broad but incomplete immunity against the Omicron variant.
Page Count	19
ISSN	21645515
Journal	Human Vaccines & Immunotherapeutics
Volume Number	18
PubMed Central reference number	PMC9897643
Issue Number	5
PubMed reference number	35499517
e-ISSN	2164554X
DOI	10.1080/21645515.2022.2062983
Language	English
Publisher	Taylor & Francis
Publisher Date	2022-05-02
Access Restriction	Open
Rights License	This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
Subject Keyword	COVID-19 SARS-CoV-2 the Omicron variant vaccines public health
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Pharmacology Immunology